Abu Dhabi’s Technology Innovation Institute Unveils the Arab World’s First Electromagnetic Compatibility Labs
Technology Innovation Institute (TII), the applied research pillar of the Advanced Technology Research Council (ATRC), today announced that its Directed Energy Research Centre (DERC) has unveiled its Electromagnetic Compatibility (EMC) laboratories in Abu Dhabi, housed in a first of its kind facility in the Arab world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210503005336/en/
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre, Technology Innovation Institute (Photo: AETOSWire)
The facility is composed of three laboratories - an EMC semi-anechoic chamber, a pulsed power laboratory, and a low-noise emanation laboratory.
The DERC facility enables key technologies to be evaluated against electromagnetic compatibility and interference by reproducing man-made and natural electromagnetic hazards in the pulsed power and semi-anechoic chambers. The direct connection between the two chambers enables a diversity of experiments involving 100’s of kV nanosecond pulses and multi-megawatt microwaves systems. The laboratories have been designed to host different categories of equipment such as connected objects of the Internet of Things, drones and autonomous cars, telecommunications equipment, medical devices, automotive equipment, IT equipment and is fully automated for tests and measurements. A unique low-noise emanation lab has been built on DERC specifications that allow for the study of very low noises emitted by electronic systems.
Electromagnetic compatibility, or EMC, allows electronic devices that are near each other to operate without mutual interference, known as Electromagnetic Interference, EMI. The operation of electronic circuits can be compromised as they can radiate or pick up unwanted interference. Highlighting the significance of EMC is the fact that the number of devices connected wirelessly is constantly on the rise.
H.E. Faisal Al Bannai, Secretary General of ATRC, said: “The launch of these labs, which are the first and the largest in the Arab world, is aligned with the Ministry of Industry and Advanced Technology’s (MoIAT) ’Operation 300bn’ which aims to advance the industrial sector, a mandate which we fully support at ATRC as the organisation defining Abu Dhabi’s and the UAE’s research strategy across academia and industry. ATRC is investing in cutting-edge laboratories that will support in-country R&D and local industry, and encourage innovation in line with international standards. By opening these unique laboratories, non-existent before in the Arab region, we want to support innovators from prototype to a qualified system.”
DERC is pioneering research in high energy physics, and the effects of high intensity fields on different materials, systems, and environments. The Centre is committed to using its cutting-edge position in science to search for practical solutions that benefit society in diverse areas. In EMC/EMI, DERC’s research domains include modelling of the EM environment produced by human-made sources; design, production, and evaluation of antennas; innovative materials for EM shielding applications; modelling of the electro-thermal response of industrial systems; and lightning protection.
Dr. Chaouki Kasmi, Chief Researcher at Directed Energy Research Centre, said: “At DERC we support research on a wide range of topics in EMC and EMI on behalf of governments and enterprises to help create and maintain advanced electronic systems. We are excited to announce the launch of the EMC labs in Abu Dhabi. They will help in pre-qualification of electronics against Electromagnetic Compatibility and Interference Standards as well as hardening of critical infrastructures to operate safely in harsh environments.”
“Many electromagnetic compatibility standards have been introduced over the years, making EMC a key part of the electronics design process,” Dr. Kasmi said. “With standards now implemented and enforced globally, manufacturers have to ensure that new electronic products meet the relevant EMC standards.”
For more information about Technology Innovation Institute (TII), visit www.tii.ae
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005336/en/
Contact information
Technology Innovation Institute
Haitham Haddadin
Haitham.Haddadin@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Scientek Corporation Sign Reseller Agreement to Boost Quantum Computing in Taiwan18.9.2025 11:11:00 EEST | Press release
IQM Quantum Computers and Scientek Corporation, a Taiwan-based reseller of scientific instruments and other high-technology products, today announced the signing of a strategic reseller agreement to accelerate the commercialisation of quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918110284/en/ IQM and Scientek Corporation sign reseller agreement The agreement follows the installation of IQM Spark, the first full-stack superconducting quantum computer at the Taiwan Semiconductor Research Institute (TSRI). Under the reseller agreement, Scientek will sell and promote IQM’s on-premises quantum computers and cloud solutions that meet the evolving needs of universities, research institutions, and enterprises. Combining Scientek's strong market presence and customer-centric approach in Taiwan with IQM’s quantum leadership, the collaboration will help Taiwanese businesses and research institutions to explore a
Acuity Knowledge Partners Acquires Ascent18.9.2025 10:30:00 EEST | Press release
Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 09:00:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the importance of the findings of the POSITIVE study and its unique approach to evaluating the long-term holistic impact of an advanced treatment in patients with moderate-to-severe psoriasis, a condition that profoundly impairs social, psychological, and physical quality of life, impacting overall well-being1. Two‑Year Real‑World Results from POSITIVE The 24-month, multinational, phase IV observational study enrolled 785 adult patients with moderate-to-severe plaque psoriasis across nine European countries
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 09:00:00 EEST | Press release
Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with confidence. This joint offering provides an end-to-end solution designed to meet evolving regulatory expectations, accelerate adoption
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 08:00:00 EEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom